Please Wait.....
Report
mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032
Market Report I 2024-08-29 I 200 Pages I EMR Inc.
mRNA Cancer Therapeutics Patent Landscape Report 2024
mRNA Cancer Therapeutics Industry Size
The mRNA cancer therapeutics market was valued at USD 13.23 billion in 2023. It is expected to grow at a CAGR of 14.6% during the forecast period of 2024-2032 and attain a market value of USD 45 billion by 2032. The patent landscape reflects the growth, showcasing innovations in treatment protocols, manufacturing processes, and immune rejection strategies, underscoring the sector's dynamic advancements and competitive development.
Patent Landscape Report Coverage
The report provides a detailed analysis of the mRNA cancer therapeutics patent landscape, focusing on key elements influencing landscape dynamics. It covers jurisdictional trends, with insights into patent activity in the United States, Europe, and Asia. The report also highlights major companies shaping the field, such as Pfizer, Moderna, and Novartis, detailing their contributions and patent portfolios. Additionally, it examines critical drivers of innovation, including advancements in mRNA stability, delivery systems, and immunogenicity. By exploring these factors, the report offers a comprehensive overview of technological progress and competitive developments in mRNA cancer therapeutics.
mRNA Cancer Therapeutics Patent Outlook
- The US has over 350 mRNA cancer therapeutics patents due to innovation and regulations. Europe has around 250 patents from collaborations and investments. Asia, mainly China and Japan, has approximately 150 patents due to progress and support.
- Key players in the patent landscape include Pfizer, Inc., with over 200 patents focusing on mRNA stability and delivery systems; Moderna, Inc., holding around 300 patents for lipid nanoparticle delivery and mRNA optimisation; and Novartis AG, with approximately 150 patents on adjuvants and scalable production techniques, driving innovation in mRNA cancer therapeutics.
- Advancements in mRNA stability, delivery systems using lipid nanoparticles and polymer-based carriers, and RNA sequence modifications with immunostimulatory adjuvants enhance immune responses against cancer cells.
mRNA Cancer Therapeutics Introduction
mRNA cancer therapeutics represent a groundbreaking approach in oncology, using messenger RNA to instruct cells to produce proteins that target and destroy cancer cells. This innovative method offers precise, personalised treatments with fewer side effects compared to traditional therapies. By leveraging the body's own cellular machinery, mRNA therapeutics can elicit strong immune responses, providing robust and adaptable cancer treatment options that hold significant promise for improving patient outcomes and advancing cancer care.
- Patent activity in mRNA cancer therapeutics is significantly driven by innovations in enhancing mRNA stability. Patents focus on chemical modifications, such as incorporating pseudouridine and 5-methylcytosine, to improve the structural integrity and longevity of mRNA. These modifications help prevent degradation and ensure sustained protein expression in cancer cells, which is crucial for maintaining therapeutic efficacy and reducing the frequency of dosing, thereby directly impacting the patent landscape.
- The development of advanced delivery systems is a major driver of patent activity in mRNA cancer therapeutics. Patents in this domain focus on lipid nanoparticles (LNPs), liposomes, and polymer-based carriers to protect mRNA and facilitate efficient cellular delivery. Innovations include targeting ligands and PEGylation to enhance delivery efficiency, minimise off-target effects, and improve the bioavailability of mRNA therapeutics. These advancements ensure precise delivery to cancer cells, boosting therapeutic effectiveness and expanding the patent landscape.
- Efforts to enhance immunogenicity are pivotal in driving patent activity in mRNA cancer therapeutics. Patents cover RNA sequence modifications, such as optimising codon usage and incorporating immunostimulatory adjuvants, to elicit stronger immune responses against cancer cells. These innovations focus on increasing protein expression and antigen presentation, improving the vaccine's efficacy. Such advancements broaden the application of mRNA cancer treatments, making them more effective and personalised, thereby contributing significantly to the expanding patent landscape.
These drivers collectively shape a dynamic and rapidly advancing patent landscape in mRNA cancer therapeutics, heralding substantial innovations and broader utilisation. Advancements in mRNA stability, delivery systems, and immunogenicity are key factors propelling this growth, ensuring the continued evolution and impact of mRNA cancer treatments in oncology.
MRNA Cancer Therapeutics Patent Segmentation Analysis
The report provides an in-depth analysis of the patents in this field by the following segmentation.
Analysis by Type
- Self-Amplifying mRNA Vaccines
- Non-Amplifying mRNA Vaccines
The mRNA cancer therapeutics patent landscape, segmented by type, is led by self-amplifying mRNA vaccines with over 400 patents filed and 150 currently in process, due to their enhanced efficacy, lower dosage requirements, and ability to generate stronger immune responses. Non-amplifying mRNA vaccines hold around 250 patents. Challenges include regulatory hurdles and manufacturing complexities. Despite these, future prospects are promising, driven by technological advancements and growing demand for effective, personalised cancer treatments.
Analysis by Route of Administration
- Intravenous
- Intramuscular
- Others
The mRNA cancer therapeutics patent landscape, segmented by route of administration, is led by intravenous administration with over 300 patents filed and 100 currently in process, due to its effectiveness in delivering precise doses directly to the bloodstream. Intramuscular routes have around 200 patents. This route leads due to its established use in clinical settings and ability to ensure rapid bioavailability. Future advancements focus on improving patient compliance and minimising side effects.
Analysis by Therapeutic Area
- Infectious Diseases
- Oncology
- Others
The mRNA cancer therapeutics patent landscape, segmented by therapeutic area, is led by oncology with over 500 patents filed and 200 currently in process. Infectious diseases follow with around 300 patents. The focus on oncology is due to its potential for significant impact on patient outcomes. Future prospects, are supported by expanding research funding, collaborative efforts, and advancements in personalised medicine, promising robust growth in this sector.
mRNA Cancer Therapeutics Patent Jurisdiction Analysis
The mRNA cancer therapeutics patent landscape shows significant activity across key jurisdictions. The United States leads with over 350 patents, driven by a strong innovation ecosystem and supportive regulatory framework. Europe follows with around 250 patents, benefitting from robust collaborative networks and significant biotech investments. Asia, particularly China and Japan, accounts for approximately 150 patents, reflecting rapid advancements and substantial government support. Each region faces challenges in harmonising patent laws and navigating regulatory complexities, but ongoing efforts in international collaboration and standardisation are expected to streamline processes, fostering further innovation and growth in mRNA cancer therapeutics globally.
Patent Profile of Key Companies
The patent landscape for mRNA cancer therapeutics is shaped by several key companies driving innovation and securing intellectual property. Here is an overview of their patent activities.
Pfizer, Inc.
Pfizer, Inc. is a key player in the mRNA cancer therapeutics patent landscape, holding over 200 patents. Their focus on innovative mRNA technologies has led to significant advancements in stabilising mRNA and enhancing delivery systems. Pfizer's strong research capabilities and strategic partnerships bolster their patent portfolio, driving forward the development of effective cancer treatments.
Modernatx Inc.
Modernatx Inc. stands at the forefront of mRNA cancer therapeutics, with a robust patent portfolio of over 300 patents. Known for their pioneering work in mRNA technology, Moderna's patents cover critical areas such as lipid nanoparticle delivery systems and mRNA sequence optimisation. Their continuous innovation and extensive clinical trials underpin their leading position in this domain.
Novartis AG
Novartis AG has established a significant presence in the mRNA cancer therapeutics patent landscape, with around 150 patents. Their patents focus on novel adjuvants and scalable production techniques, aiming to improve the efficacy and accessibility of mRNA-based cancer treatments. Novartis' investment in R&D and collaborations with research institutions drive their contributions to this field.
Other key players in the industry include Genentech Inc., Immatics Biotechnologies GmbH.
Key Questions Answered in the MRNA Cancer Therapeutics Patent Landscape Report
- What is the current industry size for mRNA cancer therapeutics?
- What is the expected growth rate of the mRNA cancer therapeutics industry?
- Which regions are leading in mRNA cancer therapeutics patents?
- Which companies are most active in mRNA cancer therapeutics patents?
- What are the key drivers of patent activity in mRNA cancer therapeutics?
- How do self-amplifying and non-amplifying mRNA vaccines differ in patents?
- What are the common routes of administration for mRNA cancer therapeutics?
- Which therapeutic areas are most covered by mRNA cancer therapeutics patents?
- What challenges exist in the patenting of mRNA cancer therapeutics?
- How do innovations in delivery systems affect mRNA cancer therapeutics patents?
- How do patent strategies impact competitive advantage?
- What are the implications of patent filings in mRNA cancer therapeutics?
- What are the challenges and opportunities in the mRNA cancer therapeutics patent landscape?
- What are the regulatory and legal considerations?
- What technological innovations have recently emerged in mRNA cancer therapeutics?
Reasons to Purchase this Report
This report provides a comprehensive analysis of the mRNA cancer therapeutics patent landscape, essential for understanding the current state and future trends of this innovative field. By examining patent activity across various segments, including type, route of administration, and therapeutic areas, the report highlights key drivers of growth and technological advancements. It offers valuable insights into the competitive landscape, key players, and jurisdictional trends. This information is crucial for stakeholders seeking to navigate the complexities of the mRNA industry, make informed strategic decisions, and identify opportunities for investment and collaboration in this rapidly evolving sector.
1 Introduction
2 Executive Summary
3 Global mRNA Vaccine and Therapeutic Market Overview
3.1 Global mRNA Vaccine and Therapeutic Market Historical Value (2017-2023)
3.2 Global mRNA Vaccine and Therapeutic Market Forecast Value (2024-2032)
4 Global mRNA Vaccine and Therapeutic Market Segmentation
4.1 Global mRNA Vaccine and Therapeutic Market Share by Type
4.1.1 Market Overview
4.1.2 Self-Amplifying mRNA Vaccines
4.1.3 Non-Amplifying mRNA Vaccines
4.2 Global mRNA Vaccine and Therapeutic Market Share by Route of Administration
4.2.1 Market Overview
4.2.2 Intravenous
4.2.3 Intramuscular
4.2.4 Intranasal
4.2.5 Others
4.3 Global mRNA Vaccine and Therapeutic Market Share by Therapeutic Area
4.3.1 Market Overview
4.3.2 Infectious Diseases
4.3.3 Oncological Disorders
4.3.4 Other Disorders
5 Global Market Dynamics
5.1 Market Drivers and Constraints
5.2 Porter's Five Forces Analysis
5.3 PESTEL Analysis
5.4 Industry Events, Initiatives, and Trends
5.5 Value Chain Analysis
6 Global mRNA Cancer Therapeutics Patent Landscape Analysis
6.1 Patent Distribution by Publication Year
6.2 Patent Distribution by Application Year
6.3 Patent Distribution by Priority Year
6.4 Analysis by Type of Patent
6.4.1 Granted Patents
6.4.2 Patent Application
6.4.3 Amended Application
6.4.4 Search Report
6.5 Analysis by Legal Status
6.5.1 Active
6.5.2 Pending
6.5.3 Expired/Discontinued
6.6 Analysis by Patent Jurisdiction
6.7 Analysis by Patent Age
6.8 Analysis by Cooperative Patent Classification (CPC) Codes
6.9 Average Time to Publish a Patent
6.9.1 By Entities
6.9.2 By Jurisdiction
6.9.3 By Technology
6.10 Analysis by Type of Entity (Academic and Non-Academic)
6.11 Analysis by Top Applicants
6.12 Analysis by Top Inventors
7 Global mRNA Cancer Therapeutics Patent Analysis by Technology
7.1 Total Patents by Top Technologies
7.2 Time Evolution of Patents by Technology
7.3 Emerging Technologies
7.4 Patent Segmentation, By Carrier
7.4.1 Time Evolution by Number of Patents
7.4.2 Time Evolution by Number of Patent Families
7.4.3 Analysis by Type of Entity (Academic vs Non-Academic)
7.4.4 Analysis by Top Applicants
7.4.5 Analysis by Top Inventors
7.5 Patent Segmentation, By Route of Administration
7.6 Patent Segmentation, By Delivery Route
*Complete technology list will be provided in the report.
8 EMR Patent Valuation Analysis
8.1 Assessment Methodology
8.2 High Value Patents
8.3 Medium Value Patents
8.4 Low Value Patents
9 Global mRNA Cancer Therapeutics - Top 10 Players Patent Analysis
9.1 Top 10 Entities by Number of Patents
9.2 Analysis by Publication Year
9.3 Analysis by Application Year
9.4 Analysis by Priority Year
9.5 Analysis by Type of Patent
9.6 Analysis by Jurisdiction
9.7 Analysis by Cooperative Patent Classification (CPC) Codes
9.8 Analysis by Source of Innovation
9.9 Analysis by Forward and Backward Citations
9.10 Analysis by Legal Status
9.11 Analysis by Patent Age
9.12 Analysis by Key Inventors
9.13 Entity Dynamics
9.13.1 Analysis by Type of Player (Academic vs Non-Academic)
9.13.2 Analysis by Collaboration
9.13.3 Analysis by Technology
9.13.4 Newcomers
9.13.4.1 Start-up Companies
9.13.4.2 Established Companies
10 Patent Profile of Key Players
10.1 Pfizer, Inc.
10.1.1 Product Portfolio
10.1.2 Patent Portfolio by Patent Families
10.1.3 Time Evolution of Patents
10.1.4 Geographical Patent Coverage
10.1.5 Patent Analysis by Technology
10.1.6 Patent News and Developments
10.1.7 Financial Analysis
10.1.8 SWOT Analysis
10.2 Modernatx Inc
10.3 Novartis AG
10.4 Genentech Inc.
10.5 Immatics Biotechnologies GmbH
11 Future Trends
12 Global mRNA Vaccine and Therapeutic Market Landscape (Additional Insight)*
12.1 Global mRNA Vaccine and Therapeutic: Developers Landscape
12.1.1 Analysis by Year of Establishment
12.1.2 Analysis by Company Size
12.1.3 Analysis by Region
12.2 Global mRNA Vaccine and Therapeutic: Product Landscape
12.2.1 Analysis by Product Type
12.2.2 Analysis by Technology
12.2.3 Analysis by Application
*Additional insights are not provided in the standard report.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security